• Investing
  • Stock
Round Table Thoughts
  • Economy
  • Editor’s Pick
Home Stock Ozempic Set the Stage, But Could Novo’s Newest Drug Be the Real Moneymaker?
Stock

Ozempic Set the Stage, But Could Novo’s Newest Drug Be the Real Moneymaker?

by March 8, 2024
by March 8, 2024 0 comment
Share
0
FacebookTwitterPinterestWhatsapp

If you ran a StockCharts scan for Runaway Gaps (Runaway Gap Ups) on Thursday, you would have come across only 12 stocks. Among them, the most recognizable name was Novo Nordisk A S (NVO), the Danish pharma company best known as the developer of the popular diabetes II drug, Ozempic.

Having already gained 26% since January, NVO jumped over 9% after reporting successful early trial results for its new weight loss drug, amycretin. Trial participants who took the drug achieved an average weight loss reduction of 13.1% over a 12-week period.

Wall Street sentiment is betting on the possibility that this new drug will be just as big as, if not bigger than, Ozempic, and some investors want to get in early. It’s easy to see why by simply looking at a weekly chart plotted over five years, covering the time when Ozempic became mainstreamed not only as a diabetes drug, but as a weight loss drug.

CHART 1: WEEKLY CHART OF NOVO. Notice the significant strength and momentum of the uptrend over a five-year period. The demand for weight loss is virtually “inelastic” these days.

Looking at the 50-, 100-, and 200-week Simple Moving Averages, not only are have they been fanning-out in full sail since Ozempic ads have began penetrating the mainstream consciousness, but NVO appears to be stretching the MAs to breaking point (if you can imagine such a thing), defying gravity with only the slightest indication (yet) of a potential pullback.

The daily picture gives us a clearer picture, not only of the strength of NOV’s performance, but of potential entry points should you want to go long.

CHART 2. DAILY CHART OF NVO. Not only does this look like a microcosm of the longer-term weekly chart, it also illustrates a similar trend relative to the broader market, its sector, and industry.

Runaway gaps, characterized as strong bullish continuation patterns, are located in the middle of a trend. But trends can only be confirmed looking backwards; we’re not there yet. So, are we looking at an exhaustion gap instead, one on the verge of a pullback?

Note the divergence between NOV’s price surge and the Money Flow Index (MFI) reading. As a volume-weighted RSI of sorts and an indicator to gauge momentum and anticipate possible reversals, the divergence we’re seeing hints at a potential dip in NVO’s share price.

Despite this, note NVO’s strong outperformance relative to the S&P 500 (+17%), its own sector via SPDR Health Care Select Sector Fund XLV (+20%), and the Dow Jones U.S. Pharmaceuticals Index or $DJUSPR (+23%).

The 50-day SMA and the Kumo segment of an Ichimoku Cloud has been plotted to show a potential landing point if a pullback were to occur. And if NVO were to pull back now, drawing a Fibonacci retracement from the October 2023 low would give us a 50% level right at $112.50, so we’re looking at the range, mostly covered within the “cloud.”

The Bottom Line

But here’s where you really have to think for yourself. Ozempic fever drove NVO’s seven-year uptrend, and arguably, it isn’t over yet. The most recent surge is driven by sentiment and speculation surrounding that amycretin will bolster and continue NVO’s winning streak. The $112 to $118 range may be a reasonable “technical” entry point, but with a PEG (Price to Earnings to Growth) ratio of 4.87, it’s far from being undervalued.

How to Run a StockCharts Scan

Finding the right stocks and exchange-traded funds (ETFs) to trade can be tricky. But with a little work, you can create a strategy that identifies a few promising prospects.

Fortunately, it isn’t too hard to learn how. Just stick to these steps:

Select (or create) a few different scan criteriaBe sure to run these scans regularlyAnalyze the stocks (or ETFs)  that your scan has identifiedDetermine your overall trading setup (including your entry and exit criteria)

The StockCharts Scan Engine is useful for narrowing down stocks and ETFs that match certain requirements. It comes with a bunch of ready-made scans that are a good starting point. As you get the hang of these scans, you can adjust them or create new ones that align with your trading goals.

For example, this article was prompted by a Runaway Gap Ups scan. As you can imagine, there are plenty more scans you can run. Try out the StockCharts Sample Scan Library (Charts & Tools > Sample Scan Library)

You Might Also Like
  • This Is The Only Segment Of The Market Worth Paying Attention To Now.
  • The Next Leading Indicator
  • Jobs Soar Past Estimates, But What Happens Next?
  • Tariff Turmoil: 3 Stocks You Need To Know Right Now!
Share
0
FacebookTwitterPinterestWhatsapp

previous post
Top 10 Actionable Charts to Watch 2024
next post
Clear Split in NY FANG+ Universe Offers Pair Trading Universe

You may also like

Top Five Charts of 2023 #4: Leadership Themes

December 22, 2023

A Simple Candle With BIG Meaning

October 30, 2024

Sector Rotation + SPY Seasonality = Trouble for Bulls?

April 30, 2025

Stock Market Ends Week on Positive Note; Market Internals May...

October 6, 2023

Breaking Down the Heavy Earnings Week

July 31, 2023

The Market is Moving Higher, BUT Avoid Real Estate in...

January 30, 2024

Is Cannabis Finally Low Enough to Go High?

June 22, 2023

Find the Strongest Price Charts with the StochClose Rank

March 5, 2023

Top 5 Stocks in “Go” Trends | Fri Aug 9,...

August 9, 2024

The Halftime Show: An In-Depth Overview of Chaikin Power Gauge...

February 21, 2023

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • OpenAI to release web browser in challenge to Google Chrome

      July 10, 2025
    • Sports executive charged with bid-rigging in Texas arena project

      July 10, 2025
    • How I Triple My Returns With 3x Leveraged ETFs!

      July 10, 2025
    • Want Faster, Lower Risk Trades? Use This Setup

      July 9, 2025
    • The Seasonality Trend Driving XLK and XLI to New Highs

      July 9, 2025

    Popular Posts

    • 1

      Biden appointee played key role in recruiting Chinese...

      June 25, 2024 3,630 views
    • 2

      Trump-era China sanctions ended by Biden may be...

      June 27, 2024 2,919 views
    • 3

      Walz’s honeymoon with China gets fresh scrutiny as...

      August 9, 2024 2,607 views
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful...

      July 10, 2024 2,576 views
    • 5

      Harris VP pick spent years promoting research facility...

      August 29, 2024 2,449 views

    Categories

    • Economy (7,009)
    • Editor's Pick (2,169)
    • Investing (538)
    • Stock (2,661)

    Popular Posts

    • 1

      Biden appointee played key role in recruiting Chinese businesses to Delaware: ‘Longtime friends’

      June 25, 2024
    • 2

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 3

      Walz’s honeymoon with China gets fresh scrutiny as Harris camp blasts ‘lying’ critics

      August 9, 2024
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful of Chinese spy threats

      July 10, 2024
    • 5

      Harris VP pick spent years promoting research facility that collaborated with ‘Chinese military company’

      August 29, 2024

    Latest News

    • OpenAI to release web browser in challenge to Google Chrome

      July 10, 2025
    • Sports executive charged with bid-rigging in Texas arena project

      July 10, 2025
    • How I Triple My Returns With 3x Leveraged ETFs!

      July 10, 2025

    Categories

    • Economy (7,009)
    • Editor's Pick (2,169)
    • Investing (538)
    • Stock (2,661)

    Disclaimer: RoundTableThoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 RoundTableThoughts.com. All Rights Reserved.

    Round Table Thoughts
    • Investing
    • Stock
    Round Table Thoughts
    • Economy
    • Editor’s Pick

    Read alsox

    Small Caps Surge, Markets React to...

    July 24, 2024

    Is the S&P 500 In Late...

    February 4, 2023

    DP Trading Room: Beware These Groups...

    May 8, 2023
    Sign In

    Keep me signed in until I sign out

    Forgot your password?

    Password Recovery

    A new password will be emailed to you.

    Have received a new password? Login here